P365: SEQUENTIAL BLINATUMOMAB WITH REDUCED INTENSITY CHEMOTHERAPY FOR OLDER ADULTS WITH NEWLY DIAGNOSED PH- B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA – FINAL RESULTS OF THE ALLG ALL08 STUDY

• Shaun Fleming,
• John Reynolds,
• Ashish Bajel,
• Nicola Venn,
• John Kwan,
• John Moore,
• David Yeung,
• Nalini Pati,
• Michael Leahy,
• Sushma Kollipara,
• Emma Verner,
• Leanne Berkahn,
• Rosemary Sutton,
• Andrew Wei,
• Matthew Greenwood

Affiliations

Shaun Fleming

1 Monash University, Australian Centre for Blood Diseases, Melbourne, Australia

John Reynolds

2 The Alfred, Melbourne, Australia

Ashish Bajel

3 The Royal Melbourne Hospital, Parkville, Australia

Nicola Venn

4 Children’s Cancer Institute, Kensington, Australia

John Kwan

5 Westmead Hospital, Westmead, Australia

John Moore

6 St Vincent’s Hospital Sydney, Darlinghurst, Australia

David Yeung

7 Royal Adelaide Hospital, Adelaide, Australia

Nalini Pati

8 Canberra Hospital, Garran, Australia

Michael Leahy

9 Royal Perth Hospital, Perth, Australia

Sushma Kollipara

10 Australasian Leukaemia & Lymphoma Group, Richmond, Australia

Emma Verner

11 Concord Repatriation General Hospital, Concord, Australia

Leanne Berkahn

12 Auckland City Hospital, Auckland, New Zealand

Rosemary Sutton

4 Children’s Cancer Institute, Kensington, Australia

Andrew Wei

13 Peter MacCallum Cancer Centre, Melbourne, Australia

Matthew Greenwood

14 Royal North Shore Hospital, St Leonards, Australia